Market Cap | 1.35B | P/E | 53.75 | EPS this Y | - | Ern Qtrly Grth | 118.10% |
Income | 53.87M | Forward P/E | 8.20 | EPS next Y | - | 50D Avg Chg | -3.00% |
Sales | 629.18M | PEG | - | EPS past 5Y | -31.60% | 200D Avg Chg | 17.00% |
Dividend | N/A | Price/Book | 0.78 | EPS next 5Y | -12.95% | 52W High Chg | -15.00% |
Recommedations | 3.00 | Quick Ratio | 3.04 | Shares Outstanding | 37.58M | 52W Low Chg | 57.00% |
Insider Own | 78.48% | ROA | 0.21% | Shares Float | 8.09M | Beta | 0.56 |
Inst Own | 13.06% | ROE | 3.06% | Shares Shorted/Prior | 73.56K/47.18K | Price | 36.01 |
Gross Margin | 48.47% | Profit Margin | 8.56% | Avg. Volume | 61,387 | Target Price | 43.00 |
Oper. Margin | 5.93% | Earnings Date | Jul 24 | Volume | 15,329 | Change | -0.58% |
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
HC Wainwright & Co. | Neutral | Jan 18, 24 |
HC Wainwright & Co. | Buy | Jan 25, 23 |
HC Wainwright & Co. | Buy | Aug 15, 22 |
HC Wainwright & Co. | Buy | Jan 31, 22 |
HC Wainwright & Co. | Buy | Jan 18, 22 |
HC Wainwright & Co. | Buy | Jul 28, 21 |
HC Wainwright & Co. | Buy | Jun 2, 21 |
HC Wainwright & Co. | Buy | Feb 1, 21 |
HC Wainwright & Co. | Buy | Nov 23, 20 |